Gracial ProdMonograph_cover - epgonline.org

References
Lunsen HW van. Recent oral contraceptive use patterns in four European
countries: evidence for selective prescribing of oral contraceptives containing
third generation progestogens. Eur J Contracept Reprod Health Care 1996; 1:
39–45
Madden S, Back DJ, Martin CA, Orme ML’E. Metabolism of the contraceptive
steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol 1989; 27:
295–9
Madden S, Back DJ, Orme ML’E. Metabolism of the contraceptive steroid
desogestrel by human liver in vitro. J Steroid Biochem 1990; 35: 281–8
Melief R. Comparative study of the effect on acne of a new desogestrelcontaining
combiphasic oral contraceptive with one containing cyproterone
acetate. Eur J Contracept Reprod Health Care 2000; 5 (Suppl 1): 71, 1–31
(Poster presented at ESC congress, Ljubljana, 2000)
Ness et al. Risk of ovarian cancer in relation to estrogen and progestin dose
and the characteristics of oral contraceptives. Am J Epidemiol 2000; 152(3):
233–41
Newton JR. Classification and comparison of oral contraceptives containing
new generation progestogens. Hum Reprod Update 1995; 1(3): 231–63
Oddens BJ, Arnolds HT, Maris MGM van, Lunsen HW van. The dynamics of oral
contraceptive use: starting, discontinuation and switching in the Netherlands
1990–93. Accepted for publication in Advances in Contraception, 1994
Organon Scientific Development Group. Data on file, 1980
Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O. Author’s reply
(Letter). Lancet 1996; 347: 547
Purba HS, Maggs JL, Orme ML’E, Back DJ, Park BK. The metabolism of 17
alpha-ethinylestradiol by human liver microsomes: formation of catechol and
chemically reactive metabolites. Br J Clin Pharmacol 1987; 23: 447–53
Royal College of General Practitioners. Oral contraceptives and health. New
York: Pitman Publishing Co, 1974
Royal College of General Practitioners Oral Contraceptive Study. Oral
contraceptives, venous thrombosis and varicose veins. Journal of the Royal
College of General Practitioners 1978; 28: 393–9
Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and
oral contraceptives: and epidemiological case-control study. Am J Epidemiol
1969; 90: 365–70
Skouby SO. The influence on pituitary ovarian function, cervical mucus and
vaginal cytology of a new progestational compound. Contraception 1976; 14:
529–39
Speck U, Wendt H, Schulze PE, Jentsch D. Bioavailability and
pharmacokinetics of cyproterone acetate 14C and ethinylestradiol 3H after
oral administration as a coated tablet. Contraception 1976; 14: 151–63
Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third
generation oral contraceptives and risk of venous thromboembolic disorders:
an international case-control study. BMJ 1996; 312: 83–8
Stanford JL. Oral contraceptives and neoplasia of the ovaries. Contraception
1991; 43: 543–56
Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use
of newer oral contraceptives and the risk of venous thromboembolism.
Contraception 1997; 56: 141–6
46